Bringing Psychedelics to Life with Revive Therapeutics

What does this mean for the Psychedelics Industry when the US Military invests $27 million?

Derek Welsh, Founder of Psilocin and COO of Psilocin Pharma (a division of Revive Therapeutics), joins The Dales Report to explain what it means, and the breakthroughs the industry will present over the next 12-24 months.

DisclaimerThe principle(s) of The Dales Report has an existing position in Revive Therapeutics. The article is neither a solicitation nor endorsement to purchase the profiled security. There is substantial risk purchasing Revive Therapeutics based on the information provided, and has been published for informational purposes only. The principle(s) may divest or make additional purchases of securities without further notice. Please contact a licensed investment advisor if you are considering investing in Revive Therapeutics.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More